ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 102,33
0,13%
Dow Jones
39 065,26
-1,53%
DAX
18 691,32
0,05%
Brent Oil
81,31
-0,27%
Bitcoin
67 628,79
-2,13%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Vertex Pharmaceuticals Inc (VRTX)

  7. Vertex Pharmaceuticals Inc (VRTX) Actualités

VRTX

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:VRTX
DateHeureSourceTitreSymboleSociété
22/05/202422h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
22/05/202422h05Business WireVertex to Participate in Upcoming June Investor ConferencesNASDAQ:VRTXVertex Pharmaceuticals Inc
22/05/202419h45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
20/05/202414h36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
20/05/202414h25Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:VRTXVertex Pharmaceuticals Inc
17/05/202422h16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
15/05/202416h30Business WireJennifer Schneider Elected to Vertex Board of DirectorsNASDAQ:VRTXVertex Pharmaceuticals Inc
07/05/202422h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRTXVertex Pharmaceuticals Inc
07/05/202413h46IH Market NewsDisney Slashes Streaming Losses, UBS shoots up 9% as profit triples expectations, and More in EarningsNASDAQ:VRTXVertex Pharmaceuticals Inc
06/05/202422h01Business WireVertex Reports First Quarter 2024 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
06/05/202414h09IH Market NewsIndex Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices RiseNASDAQ:VRTXVertex Pharmaceuticals Inc
26/04/202417h43Business WireVertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and OlderNASDAQ:VRTXVertex Pharmaceuticals Inc
23/04/202406h45PR Newswire (Canada)VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETESNASDAQ:VRTXVertex Pharmaceuticals Inc
18/04/202414h00Business WireVertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic PainNASDAQ:VRTXVertex Pharmaceuticals Inc
11/04/202413h24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:VRTXVertex Pharmaceuticals Inc
10/04/202422h01Business WireVertex Enters Into Agreement to Acquire Alpine Immune SciencesNASDAQ:VRTXVertex Pharmaceuticals Inc
09/04/202422h05Business WireVertex to Announce First Quarter 2024 Financial Results on May 6NASDAQ:VRTXVertex Pharmaceuticals Inc
01/04/202417h00PR Newswire (Canada)Vertex annonce que la présentation de drogue nouvelle d'Exagamglogène Autotemcel (exa-cel) a été acceptée pour évaluation prioritaire par Santé Canada pour le traitement de l'anémie falciforme et de la bêta-thalassémie dépendante des transfusionNASDAQ:VRTXVertex Pharmaceuticals Inc
01/04/202417h00PR Newswire (Canada)Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaNASDAQ:VRTXVertex Pharmaceuticals Inc
01/04/202414h00Business WireVertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney DiseaseNASDAQ:VRTXVertex Pharmaceuticals Inc
21/03/202413h00Business WireVertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:VRTXVertex Pharmaceuticals Inc
23/02/202413h10Business WireVertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and OlderNASDAQ:VRTXVertex Pharmaceuticals Inc
20/02/202422h05Business WireVertex to Participate in Upcoming Investor ConferencesNASDAQ:VRTXVertex Pharmaceuticals Inc
13/02/202407h59Business WireEuropean Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaNASDAQ:VRTXVertex Pharmaceuticals Inc
10/02/202400h19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VRTXVertex Pharmaceuticals Inc
06/02/202412h14IH Market NewsBoeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and MoreNASDAQ:VRTXVertex Pharmaceuticals Inc
05/02/202422h06Business WireVertex Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
05/02/202422h01Business WireVertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
30/01/202412h28Business WireVertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute PainNASDAQ:VRTXVertex Pharmaceuticals Inc
25/01/202419h48Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VRTXVertex Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VRTX

Dernières Valeurs Consultées

BIT
UV8B1M
UniCredit Bank
NYSE
OMC
Omnicom
ASX
ICP
Icash Payment Systems
COIN
JOYSSEUR
Joys Digital
NASDAQ
LIFE
aTyr Pharma
ASX
WEBKOQ
EU
JPCLE
Euronext JPN Screened Cl...
BIT
EMSA
Exchange Traded
USOTC
SNNAF
Sienna Resources (PK)
EU
3456S
3456S
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés